Reports Outline Graft-Versus-Host Disease Research from H. Lee Moffitt Cancer Center and Research Institute (Ibrutinib for therapy of steroid-refractory chronic graft vs. host disease: A multicenter real-world analysis).

The article discusses a multicenter real-world analysis of using Ibrutinib therapy for steroid-refractory chronic graft-versus-host disease (SR-cGVHD). The study involved 270 patients from 19 centers and found that Ibrutinib showed activity in treating SR-cGVHD, with a 6-month overall response rate of 45%. Factors like age, baseline prednisone, and lung involvement were associated with worse failure-free survival. The research provides insights into response factors, failure-free survival, and the toxicity profile of Ibrutinib therapy for SR-cGVHD. [Extracted from the article]